Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

19.6K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
19.6K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

2.9K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.9K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

6.2K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.2K
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

4.3K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
4.3K
Adrenergic Agonists: Indirect-Acting Agents01:25

Adrenergic Agonists: Indirect-Acting Agents

3.0K
Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
3.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Qualitative and quantitative evaluation of Fetal Bovine Serum composition: toward ethical and best quality <i>in vitro</i> science.

NAM journal·2026
Same author

Acute or repeated exposure of aerosolized flame retardants induces molecular and structural alterations in lung slices.

Toxicology·2026
Same author

Advancing regulatory use of NAMs for Chemical Safety Assessment: Progress in Brazil.

Regulatory toxicology and pharmacology : RTP·2026
Same author

Erratum: Workshop report-Vulnerability in multi-hazard risks: Addressing its complexity and dynamics.

iScience·2026
Same author

Workshop report-Vulnerability in multi-hazard risks: Addressing its complexity and dynamics.

iScience·2026
Same author

A sustainable tissue-specific hydrogel from decellularized corneal ECM for 3D In vitro ocular models.

Experimental eye research·2025

Related Experiment Video

Updated: Apr 5, 2026

Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay
05:17

Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay

Published on: February 9, 2021

2.1K

4-Nerolidylcatechol analogues as promising anticancer agents.

Alane Pereira Cortez1, Renato Ivan de Ávila1, Carla Rosane Mendanha da Cunha1

  • 1Laboratory of Cellular Pharmacology and Toxicology - LFTC/FARMATEC, Faculty of Pharmacy, Federal University of Goiás, Goiânia, GO, Brazil.

European Journal of Pharmacology
|August 23, 2015
PubMed
Summary

Synthetic analogues of 4-Nerolidylcatechol (1) show potent anticancer effects against leukemia cells. Compounds (3) and (5) induce apoptosis and mitochondrial dysfunction, suggesting potential for preclinical development.

Keywords:
4-Nerolidylcatechol analoguesAnticancer agentsApoptosis

More Related Videos

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

11.7K
Formation of Covalent DNA Adducts by Enzymatically Activated Carcinogens and Drugs In Vitro and Their Determination by 32P-postlabeling
09:33

Formation of Covalent DNA Adducts by Enzymatically Activated Carcinogens and Drugs In Vitro and Their Determination by 32P-postlabeling

Published on: March 20, 2018

14.5K

Related Experiment Videos

Last Updated: Apr 5, 2026

Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay
05:17

Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay

Published on: February 9, 2021

2.1K
Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

11.7K
Formation of Covalent DNA Adducts by Enzymatically Activated Carcinogens and Drugs In Vitro and Their Determination by 32P-postlabeling
09:33

Formation of Covalent DNA Adducts by Enzymatically Activated Carcinogens and Drugs In Vitro and Their Determination by 32P-postlabeling

Published on: March 20, 2018

14.5K

Area of Science:

  • Pharmacology and Toxicology
  • Cancer Biology
  • Natural Product Chemistry

Background:

  • 4-Nerolidylcatechol (1), isolated from Pothomorphe umbellata, exhibits promising antitumor properties but suffers from instability.
  • Developing stable, potent anticancer agents is a critical area of research, particularly for multidrug-resistant cancers.
  • Molecular simplification of natural products can yield stable analogues with retained or enhanced bioactivity.

Purpose of the Study:

  • To evaluate the cytotoxic effects of 4-Nerolidylcatechol analogues (LQFMs 2-6) against multidrug-resistant K562 leukemia cells.
  • To elucidate the cell death pathways induced by these novel compounds.
  • To assess the potential of these analogues as candidates for preclinical anticancer studies.

Main Methods:

  • Cytotoxicity assays were performed on K562 cells treated with compounds (2-6).
  • Cell morphology, apoptosis markers (phosphatidylserine exposure, sub-G1 DNA content), caspase activation (caspases-3/7, -8, -9), cell cycle progression, mitochondrial dysfunction, and NF-κB activation were analyzed.
  • Inhibitor studies using z-VAD-fmk were conducted to differentiate caspase-dependent and -independent cell death pathways.

Main Results:

  • Compounds (2-6) demonstrated concentration-dependent cytotoxicity against K562 cells, with compounds (3) and (5) showing significant activity.
  • Compounds (1), (3), and (5) induced apoptosis via mitochondrial pathways, evidenced by cytochrome c release, caspase activation, and phosphatidylserine exposure.
  • Compounds (1) and (5) also modulated cell cycle progression (G0/G1 and S arrest, respectively) and NF-κB activation, while compound (1) uniquely inhibited cyclin D1.

Conclusions:

  • 4-Nerolidylcatechol analogues (3) and (5) effectively induce apoptosis and mitochondrial dysfunction in multidrug-resistant leukemia cells.
  • These LQFMs represent biocompatible, stable synthetic alternatives to 4-Nerolidylcatechol, offering potential for further preclinical investigation.
  • The findings support the development of these simplified analogues as promising anticancer drug candidates.